IBM’s Mainframe Meltdown: When AI Spending Cannibalizes the Cash Cow
Published on 07/23/2026 at 03:05 | Redaktion boerse-global.de
The technology industry has a new catchphrase for what’s happening inside International Business Machines Corp.: the “AI tax.” It describes a phenomenon where corporate IT departments redirect their budgets toward graphics processing units and AI servers, leaving traditional hardware and software contracts to wither. Right now, IBM is the poster child for this trend — and the numbers are brutal.
Shares of Big Blue are trading at €180.10, barely 0.89% above the 52-week low of €178.52. From a June 1 peak of €292.85, the stock has shed 38.5% of its value. The annualized 30-day volatility has ballooned to 83.89%, a level that would make most dividend investors blanch. For a company with more than a century of history, this is not a garden-variety correction; it’s a crisis of confidence measured in percentage points.
The Mainframe Bloodbath
IBM’s preliminary second-quarter results, released eight days ahead of schedule, confirmed what a July 6 warning had already signaled: the old guard is bleeding. The infrastructure segment saw revenue fall 7% in the quarter, but the real carnage was in the Z-mainframe business, where sales collapsed by 42%. Management acknowledged that “dozens of large orders” failed to close by the end of June as customers scrambled to secure scarce AI hardware before prices climbed further.
CEO Arvind Krishna, in an unusually candid letter to shareholders, admitted the company had not adapted quickly enough. He described the moment as the “early innings of a structural shift” — language that sounds optimistic but masks a painful reality. IBM has slashed its full-year revenue growth forecast to between 4% and 5%, down from a prior target of more than 5%. For a company that has spent years marketing its turnaround narrative, that revision carries symbolic weight far beyond the percentage points.
Should investors sell immediately? Or is it worth buying IBM?
The $64,000 Question: Deferred or Destroyed?
Investors are now fixated on a single question: Are these delayed deals merely pushed into later quarters, or are they permanently lost to the AI spending spree? Management insists that roughly one-third of the June transactions that fell through were completed in early July. The market, however, remains deeply skeptical.
The stock is down 30.70% year-to-date, and the 14-day relative strength index sits at 29.8 — deep in oversold territory. The 200-day moving average of €234.43 looms 23.18% above the current price, a gap that reflects months of eroding trust rather than a short-term wobble.
Several law firms have launched investigations into potential securities fraud, focusing on whether IBM painted too rosy a picture of its order pipeline and Z-mainframe prospects before the sell-off. It’s worth noting that these are preliminary inquiries, not filed lawsuits or findings of wrongdoing — but for a company fighting to restore credibility, the legal cloud adds an unwelcome layer of uncertainty.
Two Divergent Paths
The optimists’ case rests on analyst price targets. The consensus target stands at €239.87, implying 33.2% upside from current levels. Wedbush’s Dan Ives recently raised his target from $320 to $350, and Barclays’ Raimo Lenschow initiated coverage with an “Overweight” rating and a $350 year-end target. Historically, IBM has tended to stabilize in the months following sharp single-day declines — not a guarantee, but a pattern worth noting.
If management confirms the full-year guidance during tonight’s earnings call and provides concrete evidence that deferred deals are closing, the oversold RSI could fuel a relief rally toward the 50-day moving average of €228.82. The 100-day average at €217.89 represents another potential recovery milestone.
IBM at a turning point? This analysis reveals what investors need to know now.
The bear case, however, is equally compelling. HSBC has already downgraded the stock to “Reduce” with a target of just $191. Critics argue that the shift away from IBM’s software is structural, not cyclical. A key factor: memory manufacturers have diverted wafer capacity toward high-bandwidth memory chips for data centers, creating a storage bottleneck that IBM was slow to anticipate. If tonight’s conference call fails to demonstrate that the second-quarter shortfall was a one-off, the downside risk remains substantial.
The Verdict Window
With volatility hovering near 84%, the next 24 hours will be decisive. If Krishna and his team can convince analysts that the pipeline is intact and the full-year forecast is achievable, the stock could stabilize and begin working its way back toward technical resistance levels. If the guidance is cut or the explanations remain vague, new lows below the current 52-week trough are a real possibility.
The fundamental tension is simple but unresolved: IBM is caught between two narratives — a successful turnaround story and collateral damage from an industry transformation. Tonight’s earnings call will determine which version the market chooses to believe.
Ad
IBM Stock: New Analysis - 23 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
